search
Back to results

RNS System RESPONSE Study (RESPONSE)

Primary Purpose

Epilepsy, Partial Seizure, Neurostimulator; Complications

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
RNS System
Sponsored by
NeuroPace
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Epilepsy focused on measuring Adolescent, Medically refractory, Responsive neurostimulation, Focal onset seizures, RNS System

Eligibility Criteria

12 Years - 17 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Subject has disabling motor simple partial seizures, complex partial seizures, and/or secondarily generalized seizures. Disabling refers to seizures that are severe enough to cause injuries, or significantly impair functional ability in domains including employment, psychosocial education and mobility.
  • Subject has seizures that are distinct, stereotypical events that can be reliably counted, in the opinion of the investigator, by the subject or parent/caregiver.
  • Subject had an average of three or more disabling motor simple partial seizures, complex partial seizures and/or secondarily generalized seizures over the two most recent consecutive 30-day periods, with no 30-day period with less than two seizures per subject and/or parent/caregiver report.
  • Subject failed treatment with a minimum of two anti-seizure medications (used in appropriate doses) with adequate monitoring of compliance and the effects of treatment, as determined by the investigator.
  • Subject has undergone diagnostic testing as part of his/her standard care that has identified no more than two epileptogenic regions.
  • Subject is male or a female of childbearing potential using a reliable method of contraception (hormonal, barrier method, surgical or abstention).
  • Subject is age 12 or older but will be less than age 18 (has not reached 18th birthday) at the time of implantation with the RNS System.
  • Subject is able to maintain an electronic diary alone or with the assistance of a competent individual.
  • Subject is able to attend clinic appointments in accordance with the study schedule.
  • Subject and/or parent/guardian must be willing and able to provide informed consent and assent when appropriate.
  • Subject is not currently implanted with an RNS Neurostimulator or NeuroPace Leads.
  • In the investigator's opinion, subject is able to tolerate a neurosurgical procedure.

Exclusion Criteria:

  • Subject has been diagnosed with primarily generalized seizures.
  • Subject requires procedures that are contraindicated based on current RNS System labeling.
  • In the opinion of the investigator, the subject has a clinically significant or unstable medical condition (including alcohol and/or drug abuse) or a progressive central nervous system disease.
  • Subject has been diagnosed with active psychosis, major depression or suicidal ideation in the preceding year. Subjects with post-ictal psychiatric symptoms need not be excluded.
  • Subject is pregnant.
  • Subject is participating in a therapeutic investigational drug or other device study.
  • Subject is implanted with an electronic medical device that delivers electrical energy to the brain.
  • Subject has been diagnosed with psychogenic or non-epileptic seizures.
  • Subject has experienced unprovoked status epilepticus in the preceding year.
  • Subject is taking chronic anticoagulants.

Note: For contraindications, refer to current physician labeling (manuals) for the RNS System available at the NeuroPace website (www.neuropace.com).

Sites / Locations

  • Children's Health of Orange CountyRecruiting
  • Nicklaus Children's HospitalRecruiting
  • University of Chicago
  • Spectrum Health SystemRecruiting
  • Mayo ClinicRecruiting
  • Westchester Medical CenterRecruiting
  • Cohen Children's Medical Center
  • Mount Sinai Hospital
  • Le Bonheur Children's Foundation Research Institute

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Evaluation Group (stimulation ON)

Arm Description

Group of participants that have an RNS System implanted and are being treated with responsive stimulation.

Outcomes

Primary Outcome Measures

Short-term chronic serious adverse device effect (SADE) rate
The primary safety endpoint is the percent of subjects with serious device-related adverse events at 84 days (12 weeks) post-implant.
Responder rate at 12 months post implant
12 months post-implant

Secondary Outcome Measures

Full Information

First Posted
April 6, 2021
Last Updated
November 11, 2022
Sponsor
NeuroPace
search

1. Study Identification

Unique Protocol Identification Number
NCT04839601
Brief Title
RNS System RESPONSE Study
Acronym
RESPONSE
Official Title
RNS® System Responsive Stimulation for Adolescents With Epilepsy Study
Study Type
Interventional

2. Study Status

Record Verification Date
November 2022
Overall Recruitment Status
Recruiting
Study Start Date
October 27, 2021 (Actual)
Primary Completion Date
July 1, 2026 (Anticipated)
Study Completion Date
December 31, 2027 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
NeuroPace

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
To demonstrate that the RNS System is safe and effective as an adjunctive therapy in individuals age 12 through 17 years with medically refractory partial onset epilepsy.
Detailed Description
NeuroPace is sponsoring the RESPONSE Study with the RNS System in individuals age 12 through 17 with partial (focal) onset seizures who have undergone diagnostic testing that localized no more than 2 epileptogenic foci, are refractory to two or more antiepileptic medications, and currently have frequent and disabling seizures. For the purposes of this study, disabling seizures are defined as motor partial seizures, complex partial seizures, and/or secondarily generalized seizures. The RNS System is currently approved by the FDA for use in patients 18 years and older with hard-to-treat partial-onset seizures. The same device will be used in the RESPONSE Study. The study is a prospective open label single arm pivotal study and participants will be followed for 2 years after placement of the RNS System. The study will enroll a maximum of 200 subjects within the United States to ensure that at least 150 subjects are implanted with the RNS System. The study design includes one interim analysis which will occur after the 75th implanted patient reaches 12 months post-implant. If the study achieves its primary safety and effectiveness endpoint goals at the interim analysis, the study will be considered successful and enrollment will be stopped. If the interim analysis does not achieve the primary safety and effectiveness endpoint goals, the study will continue enrolling up to the maximum of 200 patients. A final analysis will be conducted after the 150th implanted patient reaches 12 months post-implant.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Epilepsy, Partial Seizure, Neurostimulator; Complications, Drug Resistant Epilepsy, Focal Epilepsy
Keywords
Adolescent, Medically refractory, Responsive neurostimulation, Focal onset seizures, RNS System

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
200 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Evaluation Group (stimulation ON)
Arm Type
Experimental
Arm Description
Group of participants that have an RNS System implanted and are being treated with responsive stimulation.
Intervention Type
Device
Intervention Name(s)
RNS System
Intervention Description
The RNS System provides closed loop responsive brain stimulation. The Neurostimulator monitors the electrical activity of the brain to detect abnormal activity that could lead to a seizure. If abnormal activity is detected, the neurostimulator delivers electrical stimulation to the brain through the leads to help prevent the seizure before it occurs.
Primary Outcome Measure Information:
Title
Short-term chronic serious adverse device effect (SADE) rate
Description
The primary safety endpoint is the percent of subjects with serious device-related adverse events at 84 days (12 weeks) post-implant.
Time Frame
84-days post-implant
Title
Responder rate at 12 months post implant
Description
12 months post-implant
Time Frame
The primary effectiveness endpoint is the percent of subjects with a ≥ 50% reduction in seizures at 12 months post-implant compared to the pre-implant baseline.
Other Pre-specified Outcome Measures:
Title
Device-related Serious Adverse Event (SADE) event rate
Description
The annual SADE event rate over time in subjects age 12 - 17 years implanted with the neurostimulator and/or leads during study participation will be calculated
Time Frame
Implant through 2 years post-implant
Title
Event rate of Serious Adverse Events (SAEs) of particular relevance
Description
The annual event rate of SAEs of particular relevance (device-related or not) will be calculated over time in subjects age 12 - 17 years implanted with the neurostimulator and/or leads during study participation. SAEs of particular relevance include those related to: infection intracranial hemorrhage new more disabling seizure types suicidality
Time Frame
Implant through 2 years post-implant
Title
Affective status as measured by the Beck Depression Inventory
Description
Affective status (by summary scores from the Beck Depression Inventory (BDI), either the BDI-II or Beck Youth Inventory (BYI-II), depending on age at time of the initial clinic appointment) will be described pre-implant, as well as for the post-implant months 3, 6, 9, 12 and then every four months.
Time Frame
Implant through 2 years post-implant
Title
Neuropsychological functioning as assessed by a sub-set of tests in the NIH Toolbox Cognition Battery
Description
Neuropsychological functioning as assessed by neuropsychological testing with pediatric validated, standardized inventories to assess 3 domains that include attention, memory, and vocabulary (Flanker Inhibitory Control and Attention Test, Picture Sequence Memory Test, and Picture Vocabulary Test, respectively). These inventories are taken from the NIH Toolbox Cognition Battery and will be described by presenting summary scores for the pre-neurostimulator implant period, as well as for the annual appointments.
Time Frame
Implant through 2 years post-implant
Title
Percentage change in seizure frequency
Description
The percentage change in seizure frequency will be summarized and reported by medians and responder rates for each 3-month interval beginning 4 months post-implant.
Time Frame
Implant through 2 years post-implant
Title
Quality of life as assessed by the Quality of Life in Epilepsy Inventory (QOLIE)
Description
Quality of life [by summary scores from the QOLIE-AD-48 (validated for ages 12 - 17 years) or QOLIE-31-P (validated for ages 18 and older), depending on age at time of assessment] will be described pre-neurostimulator implant, as well as at yearly time points.
Time Frame
Implant through 2 years post-implant

10. Eligibility

Sex
All
Minimum Age & Unit of Time
12 Years
Maximum Age & Unit of Time
17 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Subject has disabling motor simple partial seizures, complex partial seizures, and/or secondarily generalized seizures. Disabling refers to seizures that are severe enough to cause injuries, or significantly impair functional ability in domains including employment, psychosocial education and mobility. Subject has seizures that are distinct, stereotypical events that can be reliably counted, in the opinion of the investigator, by the subject or parent/caregiver. Subject had an average of three or more disabling motor simple partial seizures, complex partial seizures and/or secondarily generalized seizures over the two most recent consecutive 30-day periods, with no 30-day period with less than two seizures per subject and/or parent/caregiver report. Subject failed treatment with a minimum of two anti-seizure medications (used in appropriate doses) with adequate monitoring of compliance and the effects of treatment, as determined by the investigator. Subject has undergone diagnostic testing as part of his/her standard care that has identified no more than two epileptogenic regions. Subject is male or a female of childbearing potential using a reliable method of contraception (hormonal, barrier method, surgical or abstention). Subject is age 12 or older but will be less than age 18 (has not reached 18th birthday) at the time of implantation with the RNS System. Subject is able to maintain an electronic diary alone or with the assistance of a competent individual. Subject is able to attend clinic appointments in accordance with the study schedule. Subject and/or parent/guardian must be willing and able to provide informed consent and assent when appropriate. Subject is not currently implanted with an RNS Neurostimulator or NeuroPace Leads. In the investigator's opinion, subject is able to tolerate a neurosurgical procedure. Exclusion Criteria: Subject has been diagnosed with primarily generalized seizures. Subject requires procedures that are contraindicated based on current RNS System labeling. In the opinion of the investigator, the subject has a clinically significant or unstable medical condition (including alcohol and/or drug abuse) or a progressive central nervous system disease. Subject has been diagnosed with active psychosis, major depression or suicidal ideation in the preceding year. Subjects with post-ictal psychiatric symptoms need not be excluded. Subject is pregnant. Subject is participating in a therapeutic investigational drug or other device study. Subject is implanted with an electronic medical device that delivers electrical energy to the brain. Subject has been diagnosed with psychogenic or non-epileptic seizures. Subject has experienced unprovoked status epilepticus in the preceding year. Subject is taking chronic anticoagulants. Note: For contraindications, refer to current physician labeling (manuals) for the RNS System available at the NeuroPace website (www.neuropace.com).
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Kerry Flynn
Phone
650-793-5277
Email
kflynn@neuropace.com
First Name & Middle Initial & Last Name or Official Title & Degree
Tracy Courtney
Email
tcourtney@neuropace.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Martha Morrell, MD
Organizational Affiliation
NeuroPace, Inc.
Official's Role
Principal Investigator
Facility Information:
Facility Name
Children's Health of Orange County
City
Orange
State/Province
California
ZIP/Postal Code
92868
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Angelyque Lorenzana
Phone
714-509-8972
Ext
18972
Email
Angelyque.Lorenzana@choc.org
First Name & Middle Initial & Last Name & Degree
Joffre Olaya
Facility Name
Nicklaus Children's Hospital
City
Miami
State/Province
Florida
ZIP/Postal Code
33155
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mari Vega
Email
marinellie.vega@nicklaushealth.org
First Name & Middle Initial & Last Name & Degree
Marytery Fajardo
Facility Name
University of Chicago
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60637
Country
United States
Individual Site Status
Withdrawn
Facility Name
Spectrum Health System
City
Grand Rapids
State/Province
Michigan
ZIP/Postal Code
49503
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jacquelyn Davis-Dudka
Email
Jacquelyn.davis-dudka@spectrumhealth.org
First Name & Middle Initial & Last Name & Degree
Anastasia Luniova, MD
Facility Name
Mayo Clinic
City
Rochester
State/Province
Minnesota
ZIP/Postal Code
55905
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Brian Lundstrom, MD, PhD
Facility Name
Westchester Medical Center
City
Hawthorne
State/Province
New York
ZIP/Postal Code
10532
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Donika Zogejani
Phone
914-768-3970
Email
dzogejan@nymc.edu
First Name & Middle Initial & Last Name & Degree
Steve Wolf
Facility Name
Cohen Children's Medical Center
City
Lake Success
State/Province
New York
ZIP/Postal Code
11042
Country
United States
Individual Site Status
Withdrawn
Facility Name
Mount Sinai Hospital
City
New York
State/Province
New York
ZIP/Postal Code
10029
Country
United States
Individual Site Status
Withdrawn
Facility Name
Le Bonheur Children's Foundation Research Institute
City
Memphis
State/Province
Tennessee
ZIP/Postal Code
38105
Country
United States
Individual Site Status
Withdrawn

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
32690786
Citation
Nair DR, Laxer KD, Weber PB, Murro AM, Park YD, Barkley GL, Smith BJ, Gwinn RP, Doherty MJ, Noe KH, Zimmerman RS, Bergey GK, Anderson WS, Heck C, Liu CY, Lee RW, Sadler T, Duckrow RB, Hirsch LJ, Wharen RE Jr, Tatum W, Srinivasan S, McKhann GM, Agostini MA, Alexopoulos AV, Jobst BC, Roberts DW, Salanova V, Witt TC, Cash SS, Cole AJ, Worrell GA, Lundstrom BN, Edwards JC, Halford JJ, Spencer DC, Ernst L, Skidmore CT, Sperling MR, Miller I, Geller EB, Berg MJ, Fessler AJ, Rutecki P, Goldman AM, Mizrahi EM, Gross RE, Shields DC, Schwartz TH, Labar DR, Fountain NB, Elias WJ, Olejniczak PW, Villemarette-Pittman NR, Eisenschenk S, Roper SN, Boggs JG, Courtney TA, Sun FT, Seale CG, Miller KL, Skarpaas TL, Morrell MJ; RNS System LTT Study. Nine-year prospective efficacy and safety of brain-responsive neurostimulation for focal epilepsy. Neurology. 2020 Sep 1;95(9):e1244-e1256. doi: 10.1212/WNL.0000000000010154. Epub 2020 Jul 20.
Results Reference
result

Learn more about this trial

RNS System RESPONSE Study

We'll reach out to this number within 24 hrs